TTOO (T2 Biosystems) Cyclically Adjusted Revenue per Share: $72.87 (As of Sep. 2024)


TTOO T2 Biosystems Inc TTOO
12 GF Score
Price $0.00
View Full Analysis

What is T2 Biosystems Cyclically Adjusted Revenue per Share?

T2 Biosystems TTOO 12 Cyclically Adjusted Revenue per Share is $72.87 as of Sep. 2024. GuruFocus rates TTOO with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

T2 Biosystems's adjusted revenue per share for the three months ended in Sep. 2024 was $0.111. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $72.87 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-05), T2 Biosystems's current stock price is $0.002. T2 Biosystems's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $72.87. T2 Biosystems's Cyclically Adjusted PS Ratio of today is 0.00.


T2 Biosystems  (OTCPK:TTOO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

T2 Biosystems's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.002/72.87
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


T2 Biosystems Cyclically Adjusted Revenue per Share Related Terms


T2 Biosystems Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for T2 Biosystems's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems Cyclically Adjusted Revenue per Share Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 74.40 76.57

T2 Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.84 76.57 75.96 74.46 72.87

TTOO vs IDTA, NSTM, TMO: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, T2 Biosystems's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Cyclically Adjusted PS Ratio falls into.


TTOO
12GF Score
T2 Biosystems Inc TTOO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

T2 Biosystems Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, T2 Biosystems's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.111/315.3010*315.3010
=0.111

Current CPI (Sep. 2024) = 315.3010.

T2 Biosystems Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.595 234.812 0.799
201503 0.935 236.119 1.249
201506 2.778 238.638 3.670
201509 5.167 237.945 6.847
201512 4.746 236.525 6.327
201603 4.529 238.132 5.997
201606 4.074 241.018 5.330
201609 4.336 241.428 5.663
201612 2.980 241.432 3.892
201703 3.085 243.801 3.990
201706 3.114 244.955 4.008
201709 3.529 246.819 4.508
201712 4.627 246.524 5.918
201803 6.419 249.554 8.110
201806 10.264 251.989 12.843
201809 5.630 252.439 7.032
201812 4.063 251.233 5.099
201903 4.029 254.202 4.997
201906 4.063 256.143 5.001
201909 3.694 256.759 4.536
201912 6.407 256.974 7.861
202003 3.710 258.115 4.532
202006 2.121 257.797 2.594
202009 3.549 260.280 4.299
202012 5.259 260.474 6.366
202103 4.694 264.877 5.588
202106 4.321 271.696 5.014
202109 4.477 274.310 5.146
202112 4.195 278.802 4.744
202203 212.765 287.504 233.336
202206 168.886 296.311 179.710
202209 61.283 296.808 65.101
202212 74.095 296.797 78.715
202303 15.279 301.836 15.961
202306 2.428 305.109 2.509
202309 0.329 307.789 0.337
202312 0.414 306.746 0.426
202403 0.405 312.332 0.409
202406 0.138 314.175 0.138
202409 0.111 315.301 0.111

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $72.87 mean?
T2 Biosystems (TTOO) has a Cyclically Adjusted Revenue per Share of $72.87 as of Sep. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on T2 Biosystems and its competitors.
Is T2 Biosystems' Cyclically Adjusted Revenue per Share too high?
T2 Biosystems' current Cyclically Adjusted Revenue per Share is $72.87. Overall, T2 Biosystems has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does T2 Biosystems' Cyclically Adjusted Revenue per Share compare to IDTA and NSTM?
T2 Biosystems' Cyclically Adjusted Revenue per Share of $72.87 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on T2 Biosystems and its competitors. T2 Biosystems's current Cyclically Adjusted Revenue per Share is $72.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T2 Biosystems stock overvalued right now?
T2 Biosystems (TTOO) has a current Cyclically Adjusted Revenue per Share of $72.87. The current Cyclically Adjusted Revenue per Share is $72.87. T2 Biosystems' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For T2 Biosystems (TTOO), the current Cyclically Adjusted Revenue per Share is $72.87 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

T2 Biosystems Business Description

Address 101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
12GF Score

Get the complete analysis for TTOO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price